CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 2171-A |

# Specialty Guideline Management Bosulif

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-thecounter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Bosulif | bosutinib |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

* Treatment of adult and pediatric 1 years of age and older patients with newly-diagnosed or resistant or intolerant to prior therapy chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)
* Treatment of adult patients with accelerated phase (AP) or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy

### Compendial Uses2-4

* Primary treatment of patients with advanced phase CML (accelerated phase or blast phase)
* Additional therapy for CML patients after hematopoietic stem cell transplant (HSCT)
* Ph+ B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (Ph+ B-ALL/LL)
* Maintenance therapy for Ph+ B-ALL/LL patients after HSCT
* Myeloid/lymphoid neoplasms with eosinophilia and ABL1 rearrangement in chronic phase or blast phase

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

The following information is necessary to initiate the prior authorization review:

* Prior to initiation of therapy for treatment of CML or Ph+ B-ALL/LL: results of cytogenetic and/or molecular testing for detection of the Ph chromosome or the BCR::ABL gene
* For members requesting initiation of therapy with the requested medication for treatment of CML or Ph+ B-ALL/LL after experiencing resistance to prior tyrosine kinase inhibitor (TKI) therapy: results of BCR::ABL1 mutation testing including T315I, G250E, V299L, F317L mutations
* For members requesting initiation of therapy with the requested medication for treatment of myeloid and/or lymphoid neoplasms with eosinophilia: results of testing or analysis confirming ABL1 rearrangement

## Coverage Criteria

### Chronic Myeloid Leukemia (CML)1-3

Authorization of 7 months may be granted for treatment of CML that has been confirmed by detection of the Ph chromosome or BCR::ABL gene by cytogenetic and/or molecular testing when any of the following criteria are met:

* Member has not received prior therapy with a tyrosine kinase inhibitor (TKI) (e.g., dasatinib, imatinib, nilotinib, ponatinib)
* Member experienced toxicity or intolerance to prior therapy with a TKI
* Member experienced resistance to prior therapy with a TKI and results of BCR::ABL1 mutation testing are negative for all of the following: T315I, G250E, V299L, and F317L
* Member has received HSCT for CML and results of BCR::ABL1 mutation testing are negative for all of the following: T315I, G250E, V299L, and F317L

### Ph+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)/Lymphoblastic Lymphoma (B-LL)2,4

Authorization of 12 months may be granted for treatment Ph+ B-ALL/LL that has been confirmed by detection of Ph chromosome or BCR::ABL gene by cytogenetic and/or molecular testing when any of the following criteria are met:

* Member has not received prior therapy with a TKI (e.g., dasatinib, imatinib, nilotinib, ponatinib)
* Member experienced intolerance or toxicity to prior therapy with a TKI
* Member experienced resistance to prior therapy with a TKI and results of BCR::ABL1 mutation testing are negative for all of the following: T315I, G250E, V299L, and F317L
* Member has received HSCT for Ph+ B-ALL/LL and results of BCR::ABL1 mutation testing are negative for all of the following: T315I, G250E, V299L, and F317L

### Myeloid/Lymphoid Neoplasms with Eosinophilia2

Authorization of 12 months may be granted for treatment of myeloid and/or lymphoid neoplasms with eosinophilia and ABL1 rearrangement in the chronic phase or blast phase.

## Continuation of Therapy

### CML

Authorization may be granted for continued treatment of CML that has been confirmed by detection of Ph chromosome or BCR::ABL gene by cytogenetic and/ or molecular testing when either of the following criteria are met:

* Authorization of 12 months may be granted when any of the following criteria is met:
  + BCR::ABL1 is less than or equal to 10% and there is no evidence of disease progression or unacceptable toxicity while on the current regimen for members who have been receiving the requested medication for 6 months or greater
  + Member has received HSCT and there is no evidence of unacceptable toxicity or disease progression while on the current regimen
* Authorization of up to 7 months may be granted when the member has completed less than 6 months of therapy with the requested medication.

### Ph+ B-ALL/LL

Authorization of 12 months may be granted for continued treatment of B-ALL/LL when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and either of the following criteria is met:

* Member has Ph+ B-ALL/LL that has been confirmed by detection of Ph chromosome or BCR::ABL gene by cytogenetic and/ or molecular testing
* Member has received HSCT for B-ALL/LL

### Myeloid/Lymphoid Neoplasms with Eosinophilia

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

## References

1. Bosulif [package insert]. New York, NY: Pfizer Inc.; September 2023.
2. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed March 20, 2024.
3. NCCN Clinical Practice Guidelines in Oncology® Chronic Myeloid Leukemia (Version 2.2024). © 2024 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed March 20, 2024.
4. NCCN Clinical Practice Guidelines in Oncology® Acute Lymphoblastic Leukemia (Version 4.2023). © 2024 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed March 20, 2024.